Loading
A phase 2/3 trial of Abiraterone - Usual in prostate cancer, run by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, active and no longer recruiting.
Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms is a phase 2/3 interventional study registered as NCT03348670 by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, with 600 participants enrolled, started 2023-08-18 and due to reach its primary completion in 2026-11-18. Interventions recorded: Abiraterone - Usual and Abiraterone - Study.
Shares Androgen deprivation & AR pathway inhibitors, Prostate cancer and the tag pipeline.
Shares Abiraterone acetate, Prostate cancer and the tag pipeline.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prostate cancer and the tag pipeline.
Shares Abiraterone acetate, Prostate cancer and the tag pipeline.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.